About: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City
Creator	Pass, Robert Scott, ; Conway, Edward Derespina, Kim Henry, ; Kaushik, Shubhi Kim, ; Medar, Shivanand Ofori-Amanfo, George Bercow, Asher Gillen, Jennifer Ushay, M Kowalsky, Shanna Trachtman, Rebecca Asher Bercow, ; Aydin, I Aydin, Scott Bansal, B Bansal, Prerna Conway, ; Derespina, R George Ofori-Amanfo, ; Perez, Michelle Prerna, ; Seiden, Howard Soshnick, Sara Ushay, Henry
Source	Elsevier; Medline; PMC
abstract	OBJECTIVE: To assess clinical characteristics and outcomes of SARS-CoV-2 associated multisystem inflammatory syndrome in children (MIS-C). STUDY DESIGN: Children with MIS-C admitted to pediatric intensive care units (PICU) in New York City between April 23 and May 23, 2020 were included. Demographic and clinical data were collected. RESULTS: Of 33 children with MIS-C, the median age was 10 years; 61% were male; 45% were Hispanic/Latino; 39% were black. Comorbidities were present in 45%. Fever (93%) and vomiting (69%) were the most common presenting symptoms. Depressed left ventricular ejection fraction (LVEF) was found in 63% of patients with median EF of 46.6% (IQR 39.5, 52.8). C-reactive protein, procalcitonin, D-dimer, and pro-B-type natriuretic peptide levels were elevated in all patients. For treatment, intravenous immunoglobulin was used in 18 (54%), corticosteroids in 17 (51%), tocilizumab in 12 (36%), remdesivir in 7 (21%), vasopressors in 17 (51%), mechanical ventilation in 5 (15%), extracorporeal membrane oxygenation (ECMO) in 1 (3%), and intra-aortic balloon pump in 1 (3%). The LVEF normalized in 95% of those with depressed EF. All patients were discharged home with median duration of PICU stay of 4.7 (4, 8) days and hospital stay of 7.8 (6, 10.1) days. One (3%) patient died after withdrawal of care secondary to stroke while on ECMO. CONCLUSIONS: Critically ill children with COVID-19 associated MIS-C have a spectrum of severity broader than described previously but still require careful supportive intensive care. Rapid, complete clinical and myocardial recovery was almost universal.
has issue date	2020-06-14(xsd:dateTime)
bibo:doi	10.1016/j.jpeds.2020.06.045
bibo:pmid	32553861
has license	no-cc
sha1sum (hex)	9facaeb5f4b65922eae63cc39e02dd974d5108dc
schema:url	https://doi.org/10.1016/j.jpeds.2020.06.045
resource representing a document's title	Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City
has PubMed Central identifier	PMC7293760
has PubMed identifier	32553861
schema:publication	J Pediatr
resource representing a document's body	covid:9facaeb5f4b65922eae63cc39e02dd974d5108dc#body_text
is schema:about of	named entity 'Infection' covid:arg/9facaeb5f4b65922eae63cc39e02dd974d5108dc named entity 'Multisystem' named entity 'MIS-C' named entity 'Infection' named entity 'China' named entity 'antiviral' named entity 'Kravis Children's Hospital' named entity 'circulatory shock' named entity 'cytokine storm' named entity '1, 2' named entity 'SARS-CoV-2' named entity 'Respiratory Illness' named entity 'COVID-19' named entity 'cytokine storm' named entity 'myocardial injury' named entity 'Latino' named entity 'MIS-C' named entity 'KCH' named entity 'intubation' named entity 'computed tomography' named entity 'convalescent plasma therapy' named entity 'hypotension' named entity 'MIS-C' named entity 'comorbidities' named entity 'United States' named entity 'neurological examination' named entity 'inflammatory response' named entity 'Society of Critical Care Medicine' named entity 'remdesivir' named entity 'inotropic' named entity 'vasopressor' named entity 'antibody' named entity 'emesis' named entity 'SARS-CoV-2' named entity 'MIS-C' named entity 'KCH' named entity 'critically ill' named entity 'nausea' named entity 'COVID-19' named entity 'COVID' named entity 'Critical illness' named entity 'follow-up' named entity 'antigen test' named entity 'coronaviruses' named entity 'SARS-CoV-2' named entity 'immune cell' named entity 'MIS-C' named entity 'Anticoagulation' named entity 'virus' named entity 'ventricular function' named entity 'LVEF' named entity 'IVIG' named entity 'MIS' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software